Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas

Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas

(2016) Daniel B. Costa et al.   Journal of Thoracic Oncology

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers

(2016) Juliana Eng et al.   LUNG CANCER

Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort

(2015) J. Mazières et al.   ANNALS OF ONCOLOGY

Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study

(2015) Bei Yang et al.   JOURNAL OF MOLECULAR MODELING

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib

(2015) Chien-Hung Gow et al.   Journal of Thoracic Oncology

HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation

(2015) Mikiko Suzuki et al.   LUNG CANCER

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib

(2015) Bob T. Li et al.   LUNG CANCER

Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion

(2015) Tzu-Hsiu Tsai et al.   LUNG CANCER

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

(2015) Kuo-Hsuan Hsu et al.   PLoS One

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma

(2015) Ling Shan et al.   PLoS One

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor

(2014) J. K. Won et al.   ANNALS OF ONCOLOGY

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

(2014) Yen-Fu Chen et al.   Journal of Thoracic Oncology

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

(2014) Delphine R. Boulbes et al.   Molecular Oncology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetics and biomarkers in personalisation of lung cancer treatment

(2013) Rafael Rosell et al.   LANCET

Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy

(2013) Tzu-Hsiu Tsai et al.   LUNG CANCER

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

(2012) H. Greulich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR

(2011) Shang-Gin Wu et al.   Journal of Thoracic Oncology

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

(2011) Chenguang Li et al.   PLoS One

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

(2008) C.-H. Gow et al.   ANNALS OF ONCOLOGY

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

(2008) David A. Eberhard et al.   JOURNAL OF CLINICAL ONCOLOGY